Acurx Pharmaceuticals
ACXP
8 hedge funds and large institutions have $332K invested in Acurx Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
167% more funds holding
Funds holding: 3 → 8 (+5)
104% more capital invested
Capital invested by funds: $163K → $332K (+$169K)
0.02% more ownership
Funds ownership: 0.01% → 0.03% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$155K |
| 2 |
TAM
Tocqueville Asset Management
New York
|
+$47K |
| 3 |
BlackRock
New York
|
+$33.6K |
| 4 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$20.6K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Parsons Capital Management
Providence,
Rhode Island
|
-$96K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Millennium Management
New York
| $155K | +$155K | +1,505 | New |
|
|
TAM
2
Tocqueville Asset Management
New York
| $98K | +$47K | +455 | +91% |
|
|
3
BlackRock
New York
| $33K | +$33.6K | +326 | New |
|
|
PFGIA
4
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| $21K | +$20.6K | +200 | New |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $15K | +$15.5K | +150 | New |
|
|
SFA
6
Semmax Financial Advisors
Winston Salem,
North Carolina
| $6K | +$6.5K | +63 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $4K | +$1.24K | +12 | +52% |
|
|
PCM
8
Parsons Capital Management
Providence,
Rhode Island
| – | -$96K | -750 | Closed |
|
9
Wells Fargo
San Francisco,
California
| – | +$103 | +1 | New |
|
ACXP Hedge Fund Activity: Q3 2021 in Review
8 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q3 2021, worth a combined $332K — up 104% from $163K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ACXP positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $155K. The largest seller was Parsons Capital Management, exiting entirely with an estimated $96K sold.
- 8 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q3 2021, up from 3 in Q2 2021.
- Funds reported $332K of Acurx Pharmaceuticals stock for Q3 2021, up 104% quarter-over-quarter.
- 6 funds opened new Acurx Pharmaceuticals positions in Q3 2021 and 1 closed out, a net change of +5 holders.
- The largest Acurx Pharmaceuticals buyer in Q3 2021 was Millennium Management, an estimated $155K added.
- The largest Acurx Pharmaceuticals seller in Q3 2021 was Parsons Capital Management, an estimated $96K sold.
Based on aggregated 13F filings for Q3 2021.